Forte Biosciences Inc
FBRX
Company Profile
Business description
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
Contact
3060 Pegasus Park Drive
Building 6
DallasTX75247
USAT: +1 310 618-6994
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
22
Stocks News & Analysis
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.40 | 69.70 | 0.77% |
| CAC 40 | 8,613.82 | 104.18 | 1.22% |
| DAX 40 | 26,001.31 | 372.07 | 1.45% |
| Dow JONES (US) | 52,988.47 | 503.44 | 0.96% |
| FTSE 100 | 10,857.70 | 10.35 | -0.10% |
| HKSE | 26,009.40 | 124.97 | 0.48% |
| NASDAQ | 25,893.77 | 519.91 | 2.05% |
| Nikkei 225 | 63,754.90 | 607.12 | -0.94% |
| NZX 50 Index | 13,774.93 | 75.65 | 0.55% |
| S&P 500 | 7,588.95 | 99.23 | 1.32% |
| S&P/ASX 200 | 9,019.30 | 70.30 | 0.79% |
| SSE Composite Index | 3,809.66 | 22.60 | -0.59% |